https://elicio.com/press_releases/elicio-therapeutics-announces-initiation-of-its-phase-1-2-dose-escalation-study-of-eli-002-amplify-201-in-kras-driven-cancers/ 2021-06-29T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-preclinical-data-on-amp-tcr-t-combination-therapy-in-solid-tumors-at-the-car-tcr-annual-summit-2021/ 2021-09-10T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-virtual-presentation-of-data-on-its-amphiphile-cpg-adjuvant-at-the-vaccines-summit-2021/ 2021-09-17T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-updated-preclinical-data-at-the-2021-vaccines-summit-demonstrating-that-eli-005-a-lymph-node-targeted-amphiphile-vaccine-induces-potent-cellular-and-humoral-immunity-to/ 2021-09-22T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-first-patient-dosed-in-the-eli-002-amplify-201-study-in-kras-driven-cancers/ 2021-10-06T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-preclinical-data-on-amp-tcr-t-and-car-t-combination-therapies-at-the-2021-society-for-immunotherapy-of-cancer-annual-meeting/ 2021-11-12T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-moves-into-bostons-seaport-district-and-provides-update-on-programs/ 2022-03-15T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-preclinical-data-on-its-amphiphile-cpg-adjuvant-at-the-sting-tlr-targeting-therapies-summit-2022-digital-event/ 2022-03-23T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-updated-preclinical-data-at-vaccines-summit-boston-2022-on-eli-005-a-lymph-node-targeted-amphiphile-vaccine-demonstrating-it-induces-potent-cross-reactive-cellular-and-h/ 2022-03-29T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-preclinical-data-on-the-amp-peptide-vaccine-in-combination-with-tcr-t-cell-therapy-for-solid-tumors-at-the-2022-keystone-symposia-emerging-cellular-therapies/ 2022-04-29T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-appointment-of-joy-seymour-as-vice-president-head-of-regulatory-affairs-and-promotion-of-dr-peter-demuth-to-chief-scientific-officer/ 2022-05-12T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-clinical-supply-agreement-with-regeneron-to-evaluate-eli-002-in-combination-with-libtayo-cemiplimab-in-kras-driven-tumors/ 2022-05-16T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-of-preclinical-data-showing-amp-peptide-vaccine-in-combination-with-tcr-t-cell-therapy-enhances-anti-tumor-function-and-eradicates-solid-tumors/ 2022-05-23T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-design-of-ongoing-amplify-201-study-in-mutant-kras-driven-cancers-at-asco-annual-meeting-2022/ 2022-05-27T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-preclinical-data-on-amp-cpg-adjuvant-in-combination-with-ebv-vaccine-at-the-2022-keystone-symposia-viral-immunity-basic-mechanisms-and-therapeutic-applications/ 2022-07-06T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-preclinical-data-on-its-lymph-node-targeted-sars-cov-2-amphiphile-vaccine-eli-005-at-the-2022-keystone-symposia-on-viral-immunity-basic-mechanisms-and-therapeutic-appli/ 2022-07-06T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-of-preclinical-data-on-eli-005-a-lymph-node-targeted-amphiphile-vaccine-against-sars-cov-2/ 2022-09-07T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-receives-2-8-million-grant-from-the-gastro-intestinal-research-foundation-girf-to-fund-research-for-two-therapeutic-cancer-vaccines/ 2022-09-20T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-of-preclinical-data-in-science-translational-medicine-demonstrating-the-amp-platform-promotes-uptake-of-intranasal-vaccine-in-the-mucosa-amplifying-immune-res/ 2022-10-04T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-first-patient-dosed-in-phase-1-2-study-of-lymph-node-targeted-investigational-therapeutic-vaccine-eli-002-7p-amplify-7p-in-kras-nras-mutated-solid-tumors/ 2023-04-27T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-interim-data-from-the-ongoing-phase-1-study-of-investigational-therapeutic-cancer-vaccine-eli-002-in-patients-with-high-relapse-risk-pancreatic-and-colorectal-cancer-a/ 2023-05-01T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-completion-of-merger-with-angion-biomedica/ 2023-06-01T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grant-to-new-chief-financial-officer/ 2023-06-02T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-positive-interim-data-from-the-phase-1-study-of-an-investigational-therapeutic-cancer-immunotherapy-eli-002-in-patients-with-high-relapse-risk-pancreatic-and-colorectal/ 2023-06-03T00:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-completes-reverse-merger-and-provides-a-corporate-update/ 2023-06-13T10:15:04+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-of-preclinical-data-demonstrating-amp-cpg-adjuvant-can-induce-potent-and-durable-immune-response-in-epstein-barr-virus-ebv-infectious-disease-model/ 2023-12-01T11:29:33+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-updates/ 2023-12-01T11:31:51+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants/ 2023-12-01T11:36:24+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-appointment-of-megan-filoon-as-general-counsel-and-dr-thian-kheoh-as-senior-vice-president-of-biometrics/ 2023-12-01T11:37:28+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-phase-1-data-on-cancer-vaccine-candidate-eli-002-in-patients-with-high-relapse-risk-pancreatic-and-colorectal-cancers-at-the-aacr-special-conference-on-pancreatic-canc/ 2023-12-01T11:39:40+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference/ 2023-12-01T11:40:16+00:00 https://elicio.com/press_releases/elicio-therapeutics-receives-2-6-million-grant-from-the-gastro-intestinal-gi-research-foundation-to-fund-research-for-two-therapeutic-cancer-vaccines/ 2023-12-01T11:40:57+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-updated-preliminary-data-including-promising-relapse-free-survival-data-from-the-phase-1-study-of-eli-002-at-aacr-special-conference-pancreatic-cancer/ 2023-12-01T11:41:43+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancers-sitc-2023-annual-meeting/ 2023-12-01T11:43:23+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-updated-preliminary-immunogenicity-data-from-the-ongoing-phase-1-study-of-eli-002-and-new-preclinical-data-on-eli-007-and-eli-008-at-the-society-for-immunotherapy-of-cance/ 2023-12-01T11:45:03+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-updates/ 2023-12-01T11:46:12+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-precision-oncology-virtual-conference/ 2023-12-22T14:39:39+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-7-0-million-private-placement-financing/ 2023-12-22T14:40:17+00:00 https://elicio.com/press_releases/nature-medicine-publishes-updated-preliminary-phase-1-data-from-elicio-therapeutics-amplify-201-phase-1-solid-tumor-study-of-eli-002/ 2024-01-09T06:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-first-patient-dosed-in-randomized-phase-2-pancreatic-cancer-study/ 2024-01-11T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-b-riley-securities-4th-annual-oncology-conference/ 2024-01-16T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-eli-002-7p-amplify-7p-trial-in-progress-poster-on-phase-1-2-study-of-lymph-node-targeted-vaccine-at-asco-gi-symposium/ 2024-01-17T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-of-preclinical-data-demonstrating-tcr-t-cell-therapy-in-combination-with-lymph-node-targeted-amphiphile-immunotherapy-enhanced-anti-tumor-function-and-eradica/ 2024-01-25T09:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference/ 2024-02-05T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-upcoming-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting/ 2024-03-06T08:57:53+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-6-0-million-private-placement-financing/ 2024-03-18T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-2023-financial-results-and-provides-corporate-updates/ 2024-03-29T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-updated-clinical-t-cell-and-antigen-spreading-response-data-from-the-ongoing-amplify-201-phase-1-study-of-eli-002-and-preclinical-data-on-eli-007-and-eli-008-at-the-aacr/ 2024-04-05T04:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-new-preliminary-data-from-the-ongoing-amplify-7p-phase-1-2-study-of-eli-002-7p-in-patients-with-mkras-driven-solid-tumors-at-the-2024-asco-annual-meeting/ 2024-04-25T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-updates/ 2024-05-15T04:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-preliminary-data-from-the-ongoing-amplify-7p-phase-1a-study-of-eli-002-7p-in-patients-with-mkras-driven-solid-tumors-at-the-2024-asco-annual-meeting/ 2024-05-23T05:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-2/ 2024-06-18T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-preliminary-disease-free-survival-analysis-from-the-ongoing-amplify-7p-phase-1a-study-of-eli-002-7p/ 2024-06-27T04:01:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-proposed-public-offering/ 2024-06-27T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-pricing-of-11-5-million-underwritten-public-offering/ 2024-06-28T09:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-closing-of-private-placement-of-20-0-million-convertible-note/ 2024-08-12T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-updates/ 2024-08-13T04:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference/ 2024-08-28T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node-targeted-mkras-specific-amphiphile-vaccines/ 2024-09-13T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-3/ 2024-09-17T08:31:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-4/ 2024-10-16T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-clinical-data-at-the-society-for-immunotherapy-of-cancer-sitc-2024-annual-meeting-and-stand-up-to-cancer-su2c-innovation-summit/ 2024-10-31T08:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-updated-translational-data-from-eli-002-phase-1-amplify-7p-study-at-the-society-for-immunotherapy-of-cancer-sitc-2024-annual-meeting/ 2024-11-07T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-updates/ 2024-11-13T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-completion-of-phase-2-amplify-7p-study-enrollment/ 2024-12-03T07:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-presents-updated-results-from-eli-002-phase-1-amplify-201-study-at-esmo-immuno-oncology-congress-2024/ 2024-12-12T07:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reaches-alignment-with-fda-on-eli-002-registrational-strategy/ 2025-01-22T07:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-10-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/ 2025-01-30T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-appoints-preetam-shah-ph-d-mba-as-chief-strategy-and-financial-officer/ 2025-03-24T07:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-2024-financial-results-and-provides-corporate-updates/ 2025-03-31T07:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grant-to-new-chief-strategy-and-financial-officer-and-other-new-hires/ 2025-04-16T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-first-quarter-2025-financial-results-and-provides-corporate-updates/ 2025-05-13T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-secures-10-million-in-financing/ 2025-06-04T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-host-virtual-kol-event-on-june-25-2025-to-discuss-amp-powered-eli-002-for-the-treatment-of-kras-mutation-driven-pancreatic-cancer/ 2025-06-17T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-positive-recommendation-by-idmc-to-continue-eli-002-7p-randomized-phase-2-study-in-pancreatic-cancer-without-modifications-to-final-analysis/ 2025-08-05T07:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-updates/ 2025-08-07T04:30:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-of-eli-002-updated-amplify-201-phase-1-follow-up-data-in-nature-medicine-for-minimal-residual-disease-mrd-positive-adjuvant-stage-patient/ 2025-08-12T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/ 2025-09-17T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-5/ 2025-09-18T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-investigator-initiated-phase-1-trial-to-be-conducted-by-memorial-sloan-kettering-cancer-center-and-funded-by-the-lustgarten-foundation-for-neoadjuvant-eli-002-7p-in-pancr/ 2025-09-29T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-robust-t-cell-responses-across-diverse-hla-backgrounds-in-ongoing-phase-2-amplify-7p-trial-2/ 2025-10-27T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-clinical-and-preclinical-data-at-the-sitc-2025-annual-meeting/ 2025-11-03T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-robust-cytolytic-mkras-specific-t-cell-responses-across-diverse-patient-hla-in-ongoing-phase-2-amplify-7p-trial-of-eli-002-7p-and-new-eli-004-preclinical-data-at-sitc/ 2025-11-07T09:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-updates/ 2025-11-13T04:01:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-appoints-veteran-cmc-and-technical-operations-executive-marc-j-wolfgang-as-chief-technology-officer/ 2025-11-19T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-antigen-spreading-to-patient-specific-neoantigens-beyond-mkras-in-ongoing-phase-2-amplify-7p-trial/ 2025-12-11T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-6/ 2025-12-16T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-7/ 2026-01-16T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-8/ 2026-02-18T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference/ 2026-02-25T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates/ 2026-03-12T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-9/ 2026-03-17T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-inducement-grants-10/ 2026-04-16T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-bank-of-america-healthcare-conference/ 2026-04-30T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-updates/ 2026-05-11T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-publication-in-peer-reviewed-journal-science-advances-highlighting-potent-and-durable-immune-responses-driven-by-companys-amp-dna-adjuvant-technology/ 2026-06-01T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-outlines-refined-phase-3-development-strategy-for-eli-002-7p-in-adjuvant-pancreatic-cancer/ 2026-06-15T07:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-multiple-complete-responses-after-eli-002-7p-treatment-and-subsequent-therapy-with-checkpoint-inhibition-in-metastatic-mkras-pancreatic-cancer/ 2026-06-17T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-added-to-russell-2000-and-russell-3000-indexes/ 2026-06-29T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering/ 2026-07-02T09:43:05+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering/ 2026-07-06T04:05:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-updates/ 2026-08-13T04:01:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-activation-of-the-investigator-initiated-phase-1-study-of-neoadjuvant-eli-002-7p-for-pancreatic-ductal-adenocarcinoma/ 2026-08-14T13:37:13+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-participate-at-the-wells-fargo-21st-annual-healthcare-conference/ 2026-08-24T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-to-participate-at-the-h-c-wainwright-28th-annual-global-investment-conference/ 2026-08-31T08:00:00+00:00 https://elicio.com/press_releases/elicio-therapeutics-announces-late-breaking-phase-2-amplify-7p-data-selected-for-proffered-paper-oral-presentation-at-esmo-congress-2026/ 2026-09-24T08:00:00+00:00